netbiz

About netbiz

This author has not yet filled in any details.
So far netbiz has created 34 blog entries.

Rewalk Robotics Ltd.

ReWalk Announces First U.S. Private Insurance Coverage for Personal System Workers’ Compensation is the First Private Insurer to Provide Payment for an Exoskeleton
Marlborough, MA — January 22, 2015 — Exoskeleton leader ReWalk Robotics announced today the first reimbursement for a personal exoskeleton system by a private U.S. insurer. This coverage comes from a health plan

Rewalk Robotics Ltd.

ReWalk Robotics announces Australian approval, distribution agreement
ReWalk Robotics has announced a collaboration with Making Strides, of Queensland, Australia. Making Strides will be the first dedicated spinal cord injury recovery center in Australia to distribute ReWalk systems in the country. ReWalk also has received approval by the Therapeutic Goods Administration (TGA) for rehabilitation and home use

Gamida Cell Ltd.

First Patient Successfully Transplanted with Cryopreserved (Frozen) NiCord® in Gamida Cell’s Ongoing Phase I/II Clinical Trial for Blood Cancers. This is the first transplantation to use a graft of ex-vivo expanded, cryopreserved, cord blood progenitor cells
Jerusalem, Israel, January 8, 2015 — Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive

Gamida Cell Ltd.

Gamida Cell’s NiCord® Receives FDA and EMA Orphan Drug Designation. NiCord® is in clinical development as a treatment for blood cancers including leukemia and lymphoma
 
Jerusalem, Israel, January 6, 2015 — Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that orphan drug designation has been granted

Rewalk Robotics Ltd.

Spaulding Rehabilitation Hospital Launches Exoskeleton Rehabilitation Program with Rewalk Robotics.
Boston, MA – December 5, 2014 – Spaulding Rehabilitation Hospital Boston, one of the leading rehabilitation hospitals in the United States, announced the development of an exoskeleton training program utilizing the ReWalk Robotics exoskeleton systems. The Select Spaulding Clinical Team has completed basic training on the

GI View

GI View Receives 510(K) FDA Clearance for the Aer-O-Scope™ Colonoscope System for Colorectal Cancer Screening. Aer-O-Scope™ is the only single use, self propelled colonoscope with full 360° Omni-directional View of the colon
Ramat Gan, Israel, December 2, 2014, GI View, developer of advanced GI screening systems, announced today that it has received FDA 510(k) clearance for

Gamida Cell Ltd.

Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company
Jerusalem, Israel, August 19, 2014 — Gamida Cell, a world leader in stem cell expansion technologies and therapeutic products, announced today that it has signed an investment and option agreement with Novartis Pharma AG (“Novartis”). According to the agreement, Novartis will invest $35 million in

Rewalk Robotics Ltd.

ReWalk Robotics Announces Reimbursement Coverage by Major German Insurance Company
YOKNEAM ILIT, ISRAEL / BERLIN, GERMANY / MARLBOROUGH, MASSACHUSETTS, September 23, 2014–ReWalk Robotics Ltd. (Nasdaq: RWLK) (d.b.a. Argo Medical Technologies in Germany) announced today that a major German insurance company is the first to reimburse a ReWalk system for Personal use. ReWalk Robotics has been working

Rewalk Robotics Ltd.

ReWalk Robotics Ltd. Files Registration Statement for Proposed Initial Public Offering
YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., July 10, 2014 — ReWalk Robotics Ltd. (“ReWalk”) today announced that it has filed a registration statement on Form F-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its ordinary shares. The

Rewalk Robotics Ltd.

ReWalk™ Personal Exoskeleton System Cleared by FDA for Home Use Revolutionary technology that allows individuals with Spinal Cord Injury, such as paraplegia, to stand & walk receives clearance for personal use in the U.S.
Marlborough, MA—June 26, 2014 — Exoskeleton leader ReWalk Robotics announced today that the U.S. Food and Drug Administration has cleared the company’s